A Study of Diagnostic Value of Golgi Protein GP73 and its Genetic Assay in Primary Hepatic Carcinoma

Abstract

This study aimed to investigate the diagnostic values of GP73 protein in patients' serum with primary hepatic carcinoma (PHC). Also GP73 mRNA expression level in peripheral blood mononuclear cells (PBMCs) and liver tissue between health controls and PHC patients was interrogated. Finally the role of combined detection of serum GP73 and alpha-fetoprotein (AFP) in high-risk population screening was evaluate, in an attempt to justify the new, sensitive, specific and rapid measure for the diagnosis and detection of PHC. Serum proteins of GP73 and AFP were examined in 73 patients with PHC, 13 patients with hepatic cirrhosis, 32 patients with hepatitis and 62 healthy subjects using enzyme-linked immunosorbent assay (ELISA). The relative expression levels of GP73 mRNA in PBMCs and liver tissues were examined by using SYBR Green quantitative reverse transcription polymerase chain reaction (RT-PCR) assay, calculated with the comparison of Cq value. In contrast to patients with cirrhosis and hepatitis, or healthy subjects, PHC patients had their serum GP73 and AFP significantly elevated (P < 0.05) while their PBMCs GP73 mRNA was not significantly different from those with cirrhosis and hepatitis, or healthy subjects (P > 0.05). The expression level of GP73 mRNA was significantly higher in PHC liver tissue than in normal liver tissue. The sensitivity for serum GP73 and AFP in PHC was 68.5% and 28.8%, respectively while that for the combined detection was up to 74%, justifying that the combined detection could prevent the false negative diagnosis by AFP alone and significantly improve the detection rate. As a new diagnostic biomarker of PHC, GP73 protein in serum was highly sensitive and specific. GP73 mRNA in PHC liver tissue specimens instead of whole blood could be used for the diagnosis of PHC as a tumor biomarker, whose detection was highly invasive, risky and afflicting otherwise. The combined detection of GP73 and AFP in serum effectively improved the diagnosis of PHC, in addition to the screening in high-risk population.

Keywords

Primary hepatic carcinoma GP73 GP73 mRNA Alpha-fetoprotein.

References

Huang

H. C.

Zheng

VanBuren

Zhao

Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 9, 219–230 (2010).

Eddy

J. A.

Sung

Genman

Price

N. D.

Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat 9, 149–159 (2010).

Spangenberg

H. C.

Thimme

Blum

H. E.

, Serum markers of hepatocellular carcinoma. Semin Liver Dis 26, 385–390 (2006).

Marrero

Romano

GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43, 1007–1012 (2005).

Mao

Yang

Sang

Zhao

Chen

Chi

Yang

Cai

Chen

Zhang

Mohanti

S. R.

Lopez-Soler

Millis

J. M.

Huang

Zhang

Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 59, 1687–1693 (2010).

Yamaoto

Imamura

Matsuyama

Kume

Ikeda

Norman

G. L.

Shums

Aoki

Hasegawa

Beck

Sugawara

Kakudo

AFP, AFP-L3, DCP and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Gastroenterol 45, 1272–1282 (2010).

Hanabata

Ohyanagi

Saitoh

Itoh

Immunohistochemical study on hepatic tumors-KM01 stains compared with AFP, CEA, CA19–9 and RAS P21. Kobe J Med Sci 37, 81–96 (1991).

C. X.

Zhang

Gao

Analysis of combinated transcatheter hepatic artery chemoembolization and factors affecting the prognosis in patients with primary hepatic carcinoma. Zhonghua Zhong Liu Za Zhi 28, 942–945 (2006).

Bjerner

Hogetveitm

Akselberg

K. Wold

Vangsnes

Paus

Bjoro

Bormer

Nustad

Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study. Scand J Clin Lab Invest 68, 703–713 (2008).

10.

Zhang

S. N.

Wang

X. N.

CEA and AFP expression in human hepatoma cells transfected with antisense IGFI-gene. World J Gastroenterol 4, 30–32 (1998).

11.

Maussier

M. L.

Valenza

Schinco

Galli

AFP, CEA, CA 19–9 and TPA in hepatocellular carcinoma. Int J Biol Markers 5, 21–126 (1990).

12.

Maestranzi

Przenmioslor

Mirchell

Sherwood

R. A.

The effect of benign and malignant liver disease on the tumor markers CA19–9 and CEA. Ann Clin Biochem 35, 99–103 (1998).

13.

Kladney

R. D.

Bulla

G. A.

Guo

Mason

A. L.

Tollefson

A. E.

Simon

D. J.

Koutoubi

Fimmel

C. J.

GP73, a novel golgilocalized protein upregulated by viral infection. Gene 249, 53–65 (2000).

14.

Kladney

R. D.

Xiaoyen

Bulla

G. A.

Brunt

E. M.

Fimmel

C. J.

Expression of GP73, a resident golgi membrane protein, in viral and non-viral liver disease. Hepatology 35, 1431–1440 (2002).

15.

Iftikhar

Kladney

R. D.

Havlioglu

Schmitt-Graff

Gusmirovic

Solomon

Luxon

B. A.

Bacon

B. R.

Fimmel

C. J.

, Disease and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 99, 1087–1095 (2004).

16.

Maitra

Thuluvath

P. J.

, GP73 and liver disease, a (Golgi) complex enigma. Am J Gastroenterol 99, 1096–1098 (2004).

17.

Block

T. M.

Comunale

M. A.

Lowman

Steel

L. F.

Romano

P. R.

Fimmel

Tennant

B. C.

London

W. T.

Evans

A. A.

Blumberg

B. S.

Dwek

R. A.

Mattu

T. S.

Mehta

A. S.

Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 102, 779–784 (2005).

18.

J. S.

D. W.

Liang

Miao

X. Y.

GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol, Humana Press Inc 4. (2009).